Passage BIO, Inc.
About Passage BIO, Inc.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$45.5M
- Total assets
- $62.3M
- Market cap
- $18.0M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Operating income
- -$49.3M
- Income tax
- $0
- Net income
- -$45.5M
- EPS (basic)
- $-14.35
- EPS (diluted)
- $-14.35
Balance sheet
- Total assets
- $62.3M
- Current assets
- $47.8M
- Total liabilities
- $43.5M
- Current liabilities
- $23.1M
- Shareholders’ equity
- $18.8M
Cash flow
- Operating cash flow
- -$31.5M
- Investing cash flow
- $40.2M
- Financing cash flow
- $23.0K
- Net cash flow
- $8.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $18.0M
- EPS (diluted)
- $-14.35
- Shares outstanding
- 3.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 28, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $45.5M.
- Trading 72% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Passage BIO, Inc..
Write a review
News about Passage BIO, Inc.
News & sentiment via Polygon.io
